Literature DB >> 27794420

Angiogenesis in the skin of SHARPIN-deficient mice with chronic proliferative dermatitis.

Harm HogenEsch1, Mario Sola2, Timothy M Stearns3, Kathleen A Silva3, Victoria E Kennedy3, John P Sundberg4.   

Abstract

Angiogenesis is a common feature of pathological processes including wound healing, tumor formation, and chronic inflammation. Chronic inflammation can also be associated with dilation or proliferation of lymph vessels. We examined blood vessels and lymphatics and the expression of pro- and anti-angiogenic genes in the skin of SHARPIN-deficient mice which spontaneously develop a chronic proliferative dermatitis (cpdm). The number of blood vessels in the dermis of cpdm mice increased with age as the inflammation progressed. Lymphatics identified by labeling for LYVE1 and podoplanin were moderately dilated, but they were not increased in number. The expression of proangiogenic Vegfa, Flt1 and anti-angiogenic Sema3a mRNA was increased. VEGFA was primarily localized in keratinocytes of cpdm skin. There was also increased expression of Ece1 and Pdpn mRNA. Podoplanin was restricted to lymphatic endothelial cells in normal skin, but fibroblasts in cpdm skin also reacted with anti-podoplanin antibodies indicating that they were activated. The expression of other angiogenic and lymphangiogenic factors was not altered or decreased. These results indicate that cpdm mice may be a useful model to study the pathogenesis of angiogenesis in chronic inflammation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Dermatitis; Lymphangiogenesis; Podoplanin; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27794420      PMCID: PMC5164954          DOI: 10.1016/j.yexmp.2016.05.015

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  40 in total

1.  Improved statistical tests for differential gene expression by shrinking variance components estimates.

Authors:  Xiangqin Cui; J T Gene Hwang; Jing Qiu; Natalie J Blades; Gary A Churchill
Journal:  Biostatistics       Date:  2005-01       Impact factor: 5.899

2.  The structure of normal skin and the morphology of atopic eczema.

Authors:  M C Mihm; N A Soter; H F Dvorak; K F Austen
Journal:  J Invest Dermatol       Date:  1976-09       Impact factor: 8.551

3.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.

Authors:  Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni
Journal:  Nat Med       Date:  2004-12-12       Impact factor: 53.440

4.  Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12.

Authors:  H HogenEsch; S E Torregrosa; D Boggess; B A Sundberg; J Carroll; J P Sundberg
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

5.  Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus.

Authors:  Makiko Kido-Nakahara; Jörg Buddenkotte; Cordula Kempkes; Akihiko Ikoma; Ferda Cevikbas; Tasuku Akiyama; Frank Nunes; Stephan Seeliger; Burcu Hasdemir; Christian Mess; Timo Buhl; Mathias Sulk; Frank-Ulrich Müller; Dieter Metze; Nigel W Bunnett; Aditi Bhargava; Earl Carstens; Masutaka Furue; Martin Steinhoff
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

6.  Morphologic and histochemical studies of atopic eczema in infants and children.

Authors:  P H PROSE; E SEDLIS
Journal:  J Invest Dermatol       Date:  1960-02       Impact factor: 8.551

7.  Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis.

Authors:  R E Seymour; M G Hasham; G A Cox; L D Shultz; H Hogenesch; D C Roopenian; J P Sundberg
Journal:  Genes Immun       Date:  2007-05-31       Impact factor: 2.676

Review 8.  Targeting of proangiogenic signalling pathways in chronic inflammation.

Authors:  Sander W Tas; Chrissta X Maracle; Emese Balogh; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543

9.  OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis.

Authors:  Tycho E T Mevissen; Manuela K Hospenthal; Paul P Geurink; Paul R Elliott; Masato Akutsu; Nadia Arnaudo; Reggy Ekkebus; Yogesh Kulathu; Tobias Wauer; Farid El Oualid; Stefan M V Freund; Huib Ovaa; David Komander
Journal:  Cell       Date:  2013-07-03       Impact factor: 41.582

10.  Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation.

Authors:  E Koczy-Baron; J Jochem; A Kasperska-Zajac
Journal:  Inflamm Res       Date:  2012-08-23       Impact factor: 4.575

View more
  4 in total

1.  Early induction of NRF2 antioxidant pathway by RHBDF2 mediates rapid cutaneous wound healing.

Authors:  Vishnu Hosur; Lisa M Burzenski; Timothy M Stearns; Michelle L Farley; John P Sundberg; Michael V Wiles; Leonard D Shultz
Journal:  Exp Mol Pathol       Date:  2017-03-06       Impact factor: 3.362

2.  68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice.

Authors:  Riikka Siitonen; Emilia Peuhu; Anu Autio; Heidi Liljenbäck; Elina Mattila; Olli Metsälä; Meeri Käkelä; Tiina Saanijoki; Ingrid Dijkgraaf; Sirpa Jalkanen; Johanna Ivaska; Anne Roivainen
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

Review 3.  SHARPIN: Role in Finding NEMO and in Amyloid-Beta Clearance and Degradation (ABCD) Pathway in Alzheimer's Disease?

Authors:  Dhanya Krishnan; Ramsekhar N Menon; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2021-01-05       Impact factor: 5.046

Review 4.  RNA-Binding Proteins: Emerging Therapeutics for Vascular Dysfunction.

Authors:  Victoria A Cornelius; Hojjat Naderi-Meshkin; Sophia Kelaini; Andriana Margariti
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.